Remedy Robotics Raises $62M Series B to Push Stroke Robot Toward FDA
Remedy Robotics raised $62M in a DCVC-led Series B to advance its AI-enabled N1 stroke-intervention robot toward UC clinical trials and potential FDA approval.
By Amara Osei
3 min read

What's News
- Remedy Robotics raised $62 million in Series B funding led by DCVC
- Only 2.8% of eligible stroke patients worldwide have access to endovascular treatment, per research cited by the company
- In October 2025, Remedy completed what it called the world's first remote neurointerventional procedures with the N1 System
- A pivotal clinical trial is planned across the University of California network, with UC clinical partners since 2021
- The N1 System is not approved for sale or clinical use in any jurisdiction and full autonomy remains under development
Remedy Robotics has raised $62 million in Series B funding to advance its AI-enabled N1 robotic system toward clinical trials and potential FDA approval for neurovascular procedures, including stroke treatment. The round was led by DCVC, according to the company. New investors UC Investments, Skip Capital and Hostplus joined, alongside existing backers Build Collective, Blackbird, Divergent Capital and KdT Ventures.
The money arrives at a decisive moment for the startup. Remedy is developing the N1 System to perform endovascular procedures across neurovascular, coronary and peripheral vascular care, though its initial regulatory push targets neurovascular intervention. The system remains under development and isn't approved for sale or clinical use in any jurisdiction, the company noted.
Why access, not just technology, drives the deal
Co-founder and CEO Dr. David Bell frames the funding around a distribution problem in emergency medicine. "Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals," Bell said. "For these time-critical conditions, that's devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common."
The numbers back him up. Remedy cites research indicating that only 2.8% of eligible stroke patients worldwide have access to endovascular treatment. The company says its technology could help expand access to specialized treatment for strokes and other cardiovascular emergencies, regardless of a patient's location.
What does the N1 System actually do?
The N1 uses machine learning to analyze medical images before procedures, simulate potential approaches and align three-dimensional and two-dimensional images in real time. It's designed to perform entire endovascular procedures robotically, with three modes of operation:
- on-site, with clinicians supervising the robot directly
- remote, with operators working from another location
- fully autonomous, a capability still under development
In October 2025, Remedy reported completing what it described as the world's first remote neurointerventional procedures using the N1 System. The company now works with more than 100 hospitals worldwide and plans to expand its clinical footprint through partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance.
Where the $62 million goes
Remedy laid out three immediate uses for the proceeds:
- a pivotal clinical trial run in partnership with the University of California
- deployment of prototype N1 Systems through its clinical partners
- continued development of the system's autonomous capabilities
CTO and co-founder Jake Sganga said the round buys both regulatory progress and engineering headroom. "This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy," Sganga said.
The University of California relationship isn't new. "We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network," Sganga said.
What happens next
The pivotal trial across the UC network is the gating item. A successful readout would move the N1 toward FDA clearance and, eventually, commercial sale in a segment where mechanical thrombectomy demand far outstrips the supply of trained neurointerventionalists. Until regulators sign off, Remedy's milestones stay pre-commercial: prototypes in partner hospitals, autonomy work in the lab, and a 2.8% global access rate the company is betting it can move.
Source: theaiinsider.tech
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,157 articles